PIK3CA mutations are also known in other solid tumors such as breast cancer where the PI3K inhibitor alpelisib is currently approved for treatment hormone receptor-positive, HER2-negative disease with progression after first-line therapy [53]. Here, PIK3CA is linked to breast cancer.